Such analyses may inform therapeutic decision-making in the setting of advanced disease with promising preclinical or early clinical data for drugs that target CD4039, IDO1, and HLA-DR, either alone or in combination with immune checkpoint blockade in carcinomas or melanoma30, 49. The gene discussed is IDO1; the disease is carcinoma.